Harnessing Proliferation for the Expansion of Stem Cell-Derived Pancreatic Cells: Advantages and Limitations
- PMID: 33716986
- PMCID: PMC7947602
- DOI: 10.3389/fendo.2021.636182
Harnessing Proliferation for the Expansion of Stem Cell-Derived Pancreatic Cells: Advantages and Limitations
Abstract
Restoring the number of glucose-responsive β-cells in patients living with diabetes is critical for achieving normoglycemia since functional β-cells are lost during the progression of both type 1 and 2 diabetes. Stem cell-derived β-cell replacement therapies offer an unprecedented opportunity to replace the lost β-cell mass, yet differentiation efficiencies and the final yield of insulin-expressing β-like cells are low when using established protocols. Driving cellular proliferation at targeted points during stem cell-derived pancreatic progenitor to β-like cell differentiation can serve as unique means to expand the final cell therapeutic product needed to restore insulin levels. Numerous studies have examined the effects of β-cell replication upon functionality, using primary islets in vitro and mouse models in vivo, yet studies that focus on proliferation in stem cell-derived pancreatic models are only just emerging in the field. This mini review will discuss the current literature on cell proliferation in pancreatic cells, with a focus on the proliferative state of stem cell-derived pancreatic progenitors and β-like cells during their differentiation and maturation. The benefits of inducing proliferation to increase the final number of β-like cells will be compared against limitations associated with driving replication, such as the blunted capacity of proliferating β-like cells to maintain optimal β-cell function. Potential strategies that may bypass the challenges induced by the up-regulation of cell cycle-associated factors during β-cell differentiation will be proposed.
Keywords: beta cell; diabetes; human pluripotent stem cell; in vitro differentiation; islet; proliferation.
Copyright © 2021 Oakie and Nostro.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Establishment of human pluripotent stem cell-derived pancreatic β-like cells in the mouse pancreas.Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3924-3929. doi: 10.1073/pnas.1702059115. Epub 2018 Mar 29. Proc Natl Acad Sci U S A. 2018. PMID: 29599125 Free PMC article.
-
In Vivo Differentiation of Stem Cell-derived Human Pancreatic Progenitors to Treat Type 1 Diabetes.Stem Cell Rev Rep. 2020 Dec;16(6):1139-1155. doi: 10.1007/s12015-020-10018-5. Stem Cell Rev Rep. 2020. PMID: 32844324 Review.
-
In vitro generation of pancreatic β-cells for diabetes treatment. I. β-like cells derived from human pluripotent stem cells.Folia Histochem Cytobiol. 2019;57(1):1-14. doi: 10.5603/FHC.a2019.0001. Epub 2019 Mar 14. Folia Histochem Cytobiol. 2019. PMID: 30869153 Review.
-
Biliary tree stem cells, precursors to pancreatic committed progenitors: evidence for possible life-long pancreatic organogenesis.Stem Cells. 2013 Sep;31(9):1966-79. doi: 10.1002/stem.1460. Stem Cells. 2013. PMID: 23847135 Free PMC article.
-
Evaluation of islets derived from human fetal pancreatic progenitor cells in diabetes treatment.Stem Cell Res Ther. 2013;4(6):141. doi: 10.1186/scrt352. Stem Cell Res Ther. 2013. PMID: 24268157 Free PMC article.
Cited by
-
Characterizing the effects of Dechlorane Plus on β-cells: a comparative study across models and species.Islets. 2024 Dec 31;16(1):2361996. doi: 10.1080/19382014.2024.2361996. Epub 2024 Jun 4. Islets. 2024. PMID: 38833523 Free PMC article.
-
Stem Cell-Derived β Cells: A Versatile Research Platform to Interrogate the Genetic Basis of β Cell Dysfunction.Int J Mol Sci. 2022 Jan 2;23(1):501. doi: 10.3390/ijms23010501. Int J Mol Sci. 2022. PMID: 35008927 Free PMC article. Review.
-
Islet Biology During COVID-19: Progress and Perspectives.Can J Diabetes. 2022 Jun;46(4):419-427. doi: 10.1016/j.jcjd.2021.11.002. Epub 2021 Nov 23. Can J Diabetes. 2022. PMID: 35589534 Free PMC article. Review.
-
Navigating challenges in human pluripotent stem cell-derived islet therapy for type 1 diabetes.Front Immunol. 2025 Aug 4;16:1625439. doi: 10.3389/fimmu.2025.1625439. eCollection 2025. Front Immunol. 2025. PMID: 40831568 Free PMC article. Review.
-
Human pluripotent stem cell-derived insulin-producing cells: A regenerative medicine perspective.Cell Metab. 2021 Apr 6;33(4):721-731. doi: 10.1016/j.cmet.2021.03.021. Cell Metab. 2021. PMID: 33826915 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical